2 Corporate Drive, First Floor
South San Francisco
About Senti Biosciences
Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Senti’s mission is to outsmart complex diseases with more intelligent medicines that will transform people’s lives. By programming cells to respond, adapt and make decisions, Senti is creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control.
Senti’s product candidates address major challenges in cancer treatment. To overcome cancer immune evasion, Senti is building cell therapies equipped with combinatorial arming gene circuits to elicit broad and sustained anti-tumor immune responses. Senti is also developing next-generation cell therapies that more precisely target and eliminate cancer cells while sparing healthy tissue.
Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, and LifeForce Capital among its investors.
Sentio Biosciences, Inc.
26 articles with Senti Biosciences
Determined to take its next-generation engineered cell therapies to the next level, BlueRock teams up with Senti Biosciences with futuristic medicines in mind.
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials
Senti Bio, a leading gene circuit company, announced presentations on its gene circuit engineered allogeneic CAR-NK cell therapy pipeline at the International Society for Cell and Gene Therapy Virtual Annual Meeting.
- Deborah Knobelman, PhD, appointed Chief Financial Officer - - Curt Herberts, MBS, promoted to Chief Operating Officer and Philip Lee, PhD, promoted to Chief Technology Officer -
Using a Regulator Dial gene circuit, Senti Bio regulated gene expression in preclinical in vivo models via FDA-approved, orally dosed NS3 inhibitors
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform
Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver Senti Bio is potentially eligible to receive upfront, opt-in and milestone payments exceeding $645 million
Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies
- Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver -
Senti Bio, a leading gene circuit company, today announced that results from its discovery-stage oncology program using allogeneic CAR-NK cells were presented during a poster session at the American Association for Cancer Research (AACR) Virtual Annual Meeting on April 10, 2021.
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting.
- Senti Bio, a leading gene circuit company, today announced that company leadership will participate in two upcoming investor conferences. SVB Leerink 10 th Annual Global Healthcare Conference Date: February 23 rd Event: 1x1 Investor Meetings Barclays Global Healthcare Conference Date: March 9 th Event: Presentation (3:00 p.m. EST) Date: March 11 th Event: 1x1 Investor Meetings
Senti Bio, a leading gene circuit company, announced that Dr. Tim Lu, the CEO of Senti Bio, will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th at 2:35 p.m. ET.
Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Presentations will showcase data on the potential of gene circuits to precisely target cancer and new preclinical data on SENTI-101
RoosterBio Partners with Senti Biosciences to Rapidly Translate Gene Circuit Cell Therapy into the ClinicCollaboration leverages cGMP clinical hMSC systems to accelerate gene modified cell therapy for solid tumors.
RoosterBio Inc. announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and
3/6/2020Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week's Movers & Shakers.
Pioneering gene circuit company recruits experienced biopharmaceutical executive to drive clinical development of its novel cell and gene therapy programs
Senti Biosciences, Inc., the gene circuit company focused on outsmarting complex diseases with intelligent medicines, will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
10/18/2019Pharma, biotech and medtech companies strengthen their executive ranks and boards with this week's Movers & Shakers.
Leading gene circuit company recruits experienced drug developer for board of directors’ position to help steward clinical translation of gene circuit therapies